| Field | Specification |
|---|---|
| Target | |
| Alternative names | Protein SOX-15; Protein SOX-12; Protein SOX-20; SOX15; SOX12; SOX20; SOX26; SOX27 |
| Gene ID | |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human GSPT1,2 recombinant protein (Position: K138-D499). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects eukaryotic peptide chain release factor GTP-binding subunit ERF3A (gene GSPT1) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 55.8 kDa, and the supplier reports an observed band at about 85 kDa.
GSPT1 (eRF3a) is a GTPase that partners with release factor eRF1 to end protein synthesis at stop codons. The eRF1–eRF3–GTP complex recognizes a stop codon in the ribosome, and GTP hydrolysis by GSPT1 lets eRF1 trigger release of the new protein. GSPT1 also takes part in nonsense-mediated mRNA decay and is a known target of certain molecular glue degraders.
| Target | Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (gene GSPT1; UniProt P15170, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 55.8 kDa |
| Observed MW | 85 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human K562 cells, human Raji cells, rat pancreas tissue, mouse pancreas tissue, mouse NIH/3T3 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human gall bladder adenosquamous carcinoma tissue, human gastric adenocarcinoma tissue, human liver cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): SiHa cells.
Samples with a confirmed signal (flow cytometry): Jurkat cells.
Immunogen
Recombinant human GSPT1,2 fragment (Lys138–Asp499), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
